Clinical Trial Update: Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue [Phase 4]

View source ↗

Summary

Phase 4 trial update reports chronic hepatitis B patients switching to tenofovir alafenamide after stopping prior nucleoside analogue therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Vemlidy (tenofovir alafenamide)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Chronic Hepatitis b, Hepatitis B Reactivation | Phase 4 | Status: ACTIVE_NOT_RECRUITING